Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Insulin resistance and familial history of breast cancer
Información de la revista
Vol. 54. Núm. 6.
Páginas 288-293 (Junio 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 54. Núm. 6.
Páginas 288-293 (Junio 2007)
Originales
Acceso a texto completo
Insulin resistance and familial history of breast cancer
Resistencia a la insulina e historia familiar de cáncer de mama
Visitas
...
Jorge N. Rezzonicoa,??
Autor para correspondencia
jorgerezzonico@yahoo.com.ar

Correspondence: Dr. J.N. Rezzonico. España 1340, Piso 12, Oficinas 20-22. (5500) Mendoza. Argentina.
, Fabiana Sayegha,b, Mariana Rezzonicoa, Eduardo Pusiolc, Francisco E. Gagob, Ernestina Masia Francésb, Silvina Brienzaa, José Luis Mansurd
a Centro Privado de Endocrinología. Mendoza. Argentina
b Servicio de Ginecología. Hospital Italiano. Mendoza. Argentina
c Cátedra de Embriología. Facultad de Medicina. Universidad Nacional de Cuyo. Mendoza. Argentina
d Centro de Endocrinología y Osteoporosis. La Plata. Buenos Aires. Argentina
Información del artículo
Objective

Insulin resistance has been linked to an increased risk of breast cancer. The main genes involved in low- to moderate-risk familial breast cancer remain to be identified. To test the hypothesis that there may be a genetic influence in insulin resistance, the present study analyzed the association of a familial history of breast cancer (low-tomoderate risk, defined as having a positive familial history of breast cancer) with insulin resistance.

Patients and method

We studied 846 healthy premenopausal women with no central obesity (NCO) (waist circumference < 88 cm) and with central obesity (CO) (waist circumference ≥ 88cm), aged 18-50 years, body mass index 18-39.9, with and without a familial history of breast cancer. There were 494 women with NCO (108 with a positive familial history and 386 without) and 352 women with CO (103 with a positive familial history and 249 without).

Results

NCO women with a positive familial history for breast cancer showed a significantly higher frequency of insulin resistance (HOMA > 2.5 or postprandial insulin > 60μUI/ml) [OR=4.26 (95% CI, 2.04-8.83), p<0.001], a higher frequency of low levels of high-density lipoprotein cholesterol (HDL-C) [OR=3.27 (95% CI, 1.96-5.46), p<0.001], a higher frequency of total cholesterol [OR=1.78 (95% CI, 1.09-2.90), p=0.01], a higher frequency of elevated total cholesterol, a higher frequency of elevated [OR=3.23 (95% CI, 2.32-4.49, p<0.001), a higher frequency of elevated triglycerides/HDL-C ratio [OR=4.45 (95% CI, 1.80-10), p<0.01] and higher frequency of neck circumference > 36.5cm [OR=4.25 (95% CI, 1.76-10.27), p<0.01]. CO women with a positive familial history for breast cancer showed a significantly higher frequency of insulin resistance [(OR = 3.40 (95% CI, 2.08-5.55, p<0.001)], a higher frequency of low levels of HDL-C (≤50mg/dl) [OR=2.51 (95% CI, 1.44-4.25), p < 0.01], a higher frequency of high triglycerides/HDL-C [OR=2.25 (95% CI, 1.38-3.69), p<0.01] and a higher frequency of neck circumference > 36.5 cm [OR = 2.08 (95% CI, 1.28-3.39), p=0.01]. In both groups basal and postprandial glycemia and the frequency of acrochordons were significantly higher in women with a positive familial history for breast cancer.

Conclusions

We describe a previously unreported association in women between a family history of low-to-moderate risk of breast cancer and insulin resistance syndrome.

Key words:
Familial breast cancer
Hyperinsulinemia
Insulin resistance
HDL-C
Acrochordons
Objetivo

Analizar si la resistencia a la insulina (IR) se asocia a un riesgo incrementado de cáncer de mama (CM). No se ha encontrado hasta el momento los principales genes de CM familiar de bajo a moderado riesgo. Nuestra hipótesis es que se relacionan con la IR. Para evaluarla estudiamos la relación de la IR con la historia familiar de CM de bajo a moderado riesgo (AF+CM).

Pacientes y método

Se estudió a 846 mujeres sanas, premenopáusicas, con edades entre 18 y 50 años, IMC 18-39,9, sin (NOC) y con (OC) obesidad central (perímetro de cintura ≥ 88 cm), con (AF+CM) y sin (AF-CM) antecedentes familiares de CM. De las 494 mujeres NOC, 108 tenían AF+CM y 386 no los tenían; y de 352 mujeres OC, 103 tenían AF+CM y 249 no los tenían.

Resultados

Las mujeres NOC con AF+CM presentaron mayor frecuencia de IR (HOMA > 2,5 o insulina posprandial > 60μUI/ml) (odds ratio [OR]=4,26; intervalo de confianza [IC] del 95%, 2,04-8,83; p<0,001), bajas cifras de colesterol de las lipoproteínas de alta densidad (cHDL ≤50mg/dl) (OR=3,27; IC del 95%, 1,96-5,46; p<0,001), colesterol total elevado (≥ 200mg/dl) (OR=1,78; IC del 95%, 1,09-2,90; p=0,01), triglicéridos (TG) elevados (≥ 150mg/dl) (OR=3,23; IC del 95%, 2,32-4,49; p<0,001), elevada razón triglicéridos cHDL (> 3,2) (OR=4,45; IC del 95%, 1,80-10,98; p<0,01) y circunferencia de cuello > 36,5 cm (OR=4,25; IC del 95%, 1,76-10,27; p<0,01). Las mujeres OC con AF+CM presentaron mayor frecuencia de IR (OR = 3,40; IC del 95%, 2,08-5,55; p<0,001), cHDL bajo (OR=2,51; IC del 95%, 1,44-4,25; p<0,01), TG/cHDL elevado (OR=2,25; IC del 95%, 1,38-3,69; p<0,01) y circunferencia de cuello > 36,5 cm (OR=2,08; IC del 95%, 1,28-3,39; p=0,01). En ambos grupos las glucemias basales y posprandiales y la frecuencia de acrocordones resultaron significativamente más elevadas en AF+CM.

Conclusiones

Describimos una asociación entre la historia familiar de CM de bajo y moderado riesgo y el síndrome de resistencia a la insulina hasta el momento no descrita.

El Texto completo está disponible en PDF
References
[1.]
C. Lopez Otin, E.P. Diamandis.
Breast and prostate cancer: an analysis of common epidemiological, genetic and biochemical features.
Endocr Rev, 19 (1998), pp. 365-396
[2.]
P. Lichtenstein, N.V. Holm, P.K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, et al.
Environmental and heritable factors in the causation of cancer-analysis cohorts of twins of Sweden, Denmark and Finland.
N Engl J Med, 343 (2003), pp. 78-85
[3.]
M.L. Slattery, R.A. Kerber.
A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database.
JAMA, 270 (1993), pp. 1563-1568
[4.]
Collaborative group on hormonal factors in breast cancer familial breast cancer.
collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.
Lancet, 358 (2001), pp. 1389-1399
[5.]
J. Peto, N. Collins, R. Barfoot, S. Seal, W. Warren, N. Rahman, et al.
Prevalence of BRCA1 and BRCA2 gene mutated in patients with early onset breast cancer.
J Nat Cancer Inst, 91 (1999), pp. 943-949
[6.]
Y. Miki, J. Swensen, D. Shattuck-Eidens, P.A. Futreal, K. Harshman, S. Tavtigian, et al.
A strong candidate for the breast and ovarian cancer, susceptibility gene, BRCA1.
Science, 266 (1994), pp. 66-71
[7.]
R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, et al.
Identification of the breast cancer susceptibility gene BRCA2.
Nature, 378 (1995), pp. 789-792
[8.]
S.G. Baker, P. Lichtenstein, J. Kaprio, N. Holm.
Genetic susceptibility to prostate, breast and colorrectal cancer among Nordic twins.
[9.]
Rezzónico JN, Sayegh F, Rezzónico M, Pusiol E, Gago FE, Masia Francés E, et al. Insulinemia en ayunas y postprandial en mujeres con cáncer de mama, cáncer de mama tratadas con tamoxifeno, enfermedades mamarias benignas e historia familiar de cáncer de mama. Presentado en el XIII Congreso Nacional de la Sociedad Argentina de Endocrinología; Buenos Aires, 6-8 de noviembre de 2003.
[10.]
Rezzónico JN, Sayegh F, Rezzónico M, Pusiol E, Gago FE, Masia Francés E, et al. Hyperinsulinemia is associated with Familial Breast Cancer. Presented in 11th World Congress of Menopause; Buenos Aires, 18-22 October 2005.
[11.]
Rezzónico JN, Sayegh F, Pusiol E, Rezzónico M, Gago FE, Masia E, et al. Asociación de cáncer de mama familiar con hiperinsulinemia. Presentado en la XL Reunión Nacional Annual de la Federación Argentina de Sociedades de Ginecología y Obstetricia. Santa Fe, Argentina, 31 de agosto-3 de septiembre de 2005.
[12.]
M.E. Del Giudice, G. Fantus, S. Ezzat, G. McKeown-Eyssen, D. Page, P.J. Goodwin, et al.
Insulin and related factors in premenopausal breast cancer risk.
Breast Cancer Res Treat, 47 (1998), pp. 111-120
[13.]
M.O. Goodarzi, X. Guo, K.D. Taylor, M.J. Quiñones, M.F. Saad, H. Yang, et al.
Lipoprotein lipase is a gene for insulin resistance in Mexican Americans.
Diabetes, 53 (2004), pp. 214-220
[14.]
M. Lean, T. Han, C. Morrison.
Waist circumference as a measure for indicating need for weight management.
BMJ, 311 (1995), pp. 158-161
[15.]
L. Ben-Noun, E. Sohar, A. Laor.
Neck circumference as a simple screening measure for identifying overweight and obese patients.
Obes Res, 9 (2001), pp. 470-477
[16.]
J.N. Rezzónico, E. Pusiol, M. Rezzónico, J. Mansur, C. Donadío, A. Martella, et al.
Acrocordones, hiperinsulinemia y parámetros antropométricos de insulinorresistencia en mujeres obesas y no obesas.
Rev Argent Endocrinol Metabol, 41 (2004), pp. 66
[17.]
Q. Mukhtar, G. Cleverly, R.E. Voorhees, J.W. McGrath.
Prevalence of acanthosis nigricans in association with hyperinsulinemia in New Mexico adolescents.
J Adolesc Health, 28 (2001), pp. 372-376
[18.]
T.M.S. Wolever, J. Chiasson, A. Csima, J.A. Hunt, C. Palmason, S.A. Ross, et al.
Variation of postprandial plasma glucose, palatability and symptoms associated with a standardized mixed test meal versus 75g oral glucose.
Diabetes Care, 21 (1998), pp. 336-340
[19.]
A. Taniguchi, M. Fukushima, M. Sakai, K. Kataoka, I. Nagata, K. Doi, et al.
The role of the body mass index and triglyceride levels in identifying insulin-sensitivity and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients.
Metabolism, 49 (2000), pp. 1001-1005
[20.]
C. Punyadeera, N.J. Crowther, M.T. Van der Merwe, M. Toman, A.R. Immelman, C.P. Schlaphoff, et al.
Metabolic response to a mixed meal in obese and lean women from two south african populations.
Obes Res, 10 (2002), pp. 1207-1216
[21.]
S. Pita Fernández, S. Pertega Díaz.
Significancia estadística y relevancia clínica.
Cad Aten Prim, 8 (2001), pp. 191-195
[22.]
M. Yilmaz, N. Bukan, R. Ersoy, A. Karakoc, I. Yetkin, G. Ayvaz, et al.
Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome.
Hum Reprod, 20 (2005), pp. 2414-2420
[23.]
B. Grunfeld, M. Balzaretti, M. Romo, M. Giménez, R. Gutman.
Hyperinsulinemia in normotensive offspring of hypertensive parents.
Hypertension, 23 (1994), pp. 12-15
[24.]
P. Iyengar, V. Espina, T.W. Williams, Y. Lin, D. Berry, L.A. Jelicks, et al.
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor-stroma microenvironment.
J Clin Invest, 115 (2005), pp. 1163-1176
[25.]
C.L. Carpenter, R.K. Ross, A. Paganini-Hill, L. Bernstein.
Effect of family history, obesity and exercise on breast cancer risk among postmenopausal women.
Int J Cancer, 106 (2003), pp. 96-102
[26.]
B.L. Wajchenberg.
Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome.
Endocr Rev, 21 (2000), pp. 697-738
[27.]
Reaven GM. Syndrome X, insulin resistance, hyperinsulinemia, and coronary heart disease. En: Goldfine ID, Rushakoff RJ, editores. Diabetes and carbohydrate metabolism. Disponible en: http://www.endotext.org/diabetes/index.htm.
[28.]
J. Pietzsch, K. Fuecker.
Increased cholesteryl ester transfer protein activity in impaired glucose intolerance relationship to high density lipoprotein metabolism.
Clin Sci, 44 (2003), pp. 171-177
[29.]
F. Tato, G. Lena Vega, S.M. Grundy.
Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations.
Arterioscler Thromb Vasc Biol, 15 (1995), pp. 446-451
[30.]
S.M. Boekholdt, F.M. Sacks, J.W. Jukema, J. Shepherd, D.J. Freeman, A.D. McMahon, et al.
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment. Individual patient meta-analysis of 13 677 subjects.
Circulation, 111 (2005), pp. 278-287
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos